Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
The deal is a late entrant into 2020's top five mergers and acquisitions.
Digital therapeutics are going from strength to strength during the pandemic.
The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.
The company’s claims of a win with its cervical precancer therapy candidate look questionable.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.